Zakharchenko Mychajlo, Los Ferdinand, Brodska Helena, Balik Martin
Dept. of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Dept. of Clinical Biochemistry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
PLoS One. 2016 Jul 8;11(7):e0158179. doi: 10.1371/journal.pone.0158179. eCollection 2016.
The requirements for magnesium (Mg) supplementation increase under regional citrate anticoagulation (RCA) because citrate acts by chelation of bivalent cations within the blood circuit. The level of magnesium in commercially available fluids for continuous renal replacement therapy (CRRT) may not be sufficient to prevent hypomagnesemia.
Patients (n = 45) on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min) with RCA modality (4% trisodium citrate) using calcium free fluid with 0.75 mmol/l of Mg with additional magnesium substitution were observed after switch to the calcium-free fluid with magnesium concentration of 1.50 mmol/l (n = 42) and no extra magnesium replenishment. All patients had renal indications for CRRT, were treated with the same devices, filters and the same postfilter ionized calcium endpoint (<0.4 mmol/l) of prefilter citrate dosage. Under the high level Mg fluid the Qb, dosages of citrate and CRRT were consequently escalated in 9h steps to test various settings.
Median balance of Mg was -0.91 (-1.18 to -0.53) mmol/h with Mg 0.75 mmol/l and 0.2 (0.06-0.35) mmol/h when fluid with Mg 1.50 mmol/l was used. It was close to zero (0.02 (-0.12-0.18) mmol/h) with higher blood flow and dosage of citrate, increased again to 0.15 (-0.11-0.25) mmol/h with 3,000 ml/h of high magnesium containing fluid (p<0.001). The arterial levels of Mg were mildly increased after the change for high level magnesium containing fluid (p<0.01).
Compared to ordinary dialysis fluid the mildly hypermagnesemic fluid provided even balances and adequate levels within ordinary configurations of CRRT with RCA and without a need for extra magnesium replenishment.
ClinicalTrials.gov Identifier: NCT01361581.
在局部枸橼酸抗凝(RCA)情况下,镁(Mg)补充需求增加,因为枸橼酸通过螯合血液回路中的二价阳离子发挥作用。用于连续性肾脏替代治疗(CRRT)的市售液体中的镁水平可能不足以预防低镁血症。
观察45例接受CRRT(2000 ml/h,血流量(Qb)100 ml/min)并采用RCA模式(4% 枸橼酸钠)的患者,他们先使用含0.75 mmol/l镁的无钙液体并额外补充镁,之后改用镁浓度为1.50 mmol/l的无钙液体(n = 42)且不再额外补充镁。所有患者均有CRRT的肾脏适应证,使用相同的设备、滤器,且滤器后离子钙终点(<0.4 mmol/l)时的滤器前枸橼酸剂量相同。在高镁液体情况下,Qb、枸橼酸剂量和CRRT以9小时为间隔逐步增加,以测试不同设置。
使用0.75 mmol/l镁时,镁的中位数平衡为 -0.91(-1.18至 -0.53)mmol/h;使用1.50 mmol/l镁的液体时,镁平衡为0.2(0.06 - 0.35)mmol/h。在更高血流量和枸橼酸剂量时接近零(0.02(-0.12至0.18)mmol/h),使用含3000 ml/h高镁液体时又升至0.15(-0.11至0.25)mmol/h(p<0.001)。改用含高镁液体后,动脉血镁水平轻度升高(p<0.01)。
与普通透析液相比,轻度高镁血症液体在采用RCA的CRRT普通配置中能提供平衡且充足的水平,无需额外补充镁。
ClinicalTrials.gov标识符:NCT01361581。